Why Is GANX Stock Rallying 22% After Hours?

The U.S. Food and Drug Administration (FDA) cleared Gain Therapeutics to begin a mid-stage clinical trial of its experimental drug GT-02287 in people with Parkinson’s disease.

• The decision allows the Bethesda, Maryland-based biotech to expand testing into the United States, with the study expected to start in the third quarter of this year.
• GT-02287 is Gain’s lead drug candidate and the first product from its Magellan AI drug-discovery platform to reach this stage of development.
• Current Parkinson’s treatments mainly ease symptoms such as tremors and stiffness but do not stop the underlying damage to brain cells.

Shares of Gain Therapeutics (GANX) jumped 21% after hours on Monday after the company announced that the U.S. Food and Drug Administration has cleared the company to begin a mid-stage clinical trial of its experimental drug GT-02287 in people with Parkinson’s disease.

The decision allows the Bethesda, Maryland-based biotech to expand testing into the United States, with the study expected to start in the third quarter of this year. The move follows encouraging results from earlier early-stage studies conducted in Australia.

The trials conducted in Australia showed the drug was generally safe and well-tolerated in both healthy volunteers and Parkinson’s patients. Researchers also observed signs that the drug engaged its intended target in the brain, along with early hints of clinical benefit. Some participants reported improvements in sense of smell and taste, balance, gait, and sleep, as per the company.

What Will The New Study Test?

The upcoming Phase 2 trial will evaluate oral GT-02287 in people with early Parkinson’s disease, including those who carry a common genetic risk factor known as a GBA1 mutation. Sites in the United States, Australia, and select European centers will take part. The study aims to further assess safety while looking for clearer signals of whether the drug can improve symptoms and slow disease progression.

GT-02287 is Gain’s lead drug candidate and the first product from its Magellan AI drug-discovery platform to reach this stage of development. The company has built much of its Parkinson’s program around this single molecule, supported by grants from major research organizations, including The Michael J. Fox Foundation. All of the company’s remaining programs are in early discovery or preclinical research phase, without yet entering human trials.

Current Parkinson’s treatments mainly ease symptoms such as tremors and stiffness but do not stop the underlying damage to brain cells. GT-02287 is designed to help restore the function of a key enzyme that becomes impaired in many Parkinson’s patients. Preclinical work and early human data suggest the drug may reduce toxic protein buildup and inflammation linked to the disease, raising hopes it could eventually slow or halt progression rather than just manage symptoms.

How Did GANX Retail Traders React?

On Stocktwits, retail sentiment around GANX jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.

A Stocktwits user voiced hopes in the drug’s potential to reverse Parkinson’s symptoms.

Another compared Gain’s drug with Roche’s prasinezumab, which also aims to slow or stop the progression of Parkinson's. Roche is currently undertaking late-stage trials for the drug.

GANX stock has fallen by about 39% year-to-date. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.<